{"blog": [], "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Mylan Inc", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Meda AB", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Perrigo Company", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Teva Pharmaceutical Industries Ltd", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/12/business/dealbook/mylans-new-deal-may-not-be-the-one-shareholders-wanted.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "343", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "pub_date": "2016-02-12T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Mylan\u2019s New Deal May Not Be the One Shareholders Wanted", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "_id": "56bce0f738f0d810e6a1a1c3", "slideshow_credits": null, "abstract": null}